10-Q: Kura Oncology Advances Ziftomenib with FDA Priority Review

Kura Oncology reports Q2 2025 financial results, highlighting significant progress in its ziftomenib program with FDA Priority Review and positive clinical data, alongside continued operating losses.

Summary

• Collaboration revenue for the three months ended June 30, 2025, was $15.3 million, and for the six months ended June 30, 2025, was $29.4 million, primarily from the Kyowa License Agreement.
• Net loss for the three months ended June 30, 2025, was $(66.1) million, and for the six months ended June 30, 2025, was $(123.6) million.
• Cash, cash equivalents, and short-term investments totaled $630.7 million as of June 30, 2025.
• The FDA accepted the New Drug Application (NDA) for ziftomenib for the treatment of adult patients with relapsed or refractory NPM1-mutant Acute Myeloid Leukemia (AML), granting Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025.
• Positive pivotal data from the Phase 1b and Phase 2 portions of the KOMET-001 trial for ziftomenib in relapsed or refractory NPM1-mutant AML were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, showing a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23%.
• Positive data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib in combination with 7+3 chemotherapy in newly diagnosed NPM1-mutant or KMT2A-rearranged AML were presented at the 2025 European Hematology Association (EHA) Congress, demonstrating a composite complete remission (CRc) rate of 93% for NPM1-mutant AML and 89% for KMT2A-rearranged AML.
• Kura Oncology initiated the KOMET-015 trial evaluating ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST).
• Plans were announced for two independent, global, randomized, double-blind, placebo-controlled Phase 3 trials (KOMET-017-IC and KOMET-017-NIC) to evaluate ziftomenib in combination with intensive and non-intensive regimens in newly diagnosed NPM1-mutant or KMT2A-rearranged AML, expected to initiate in the second half of 2025.
• A Co-Promotion and Medical Affairs Agreement with Kyowa Kirin, Inc. became effective on June 27, 2025, outlining shared responsibilities for commercialization activities for ziftomenib in the U.S. Territory.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant clinical and regulatory advancements for ziftomenib, including FDA Priority Review and strong clinical data, which are major value drivers for a biopharmaceutical company. The substantial cash runway and collaboration revenue further strengthen this positive outlook, despite ongoing operating losses which are typical for a clinical-stage company.

Positives

• The FDA accepted the NDA for ziftomenib with Priority Review, setting a PDUFA target action date of November 30, 2025, indicating an expedited review pathway.
• Ziftomenib received Breakthrough Therapy Designation for the treatment of patients with relapsed or refractory NPM1-mutant AML, underscoring its potential to offer substantial improvement over existing therapies.
• Pivotal data from the KOMET-001 Phase 2 trial demonstrated a 23% CR/CRh rate in relapsed or refractory NPM1-mutant AML, with clinically meaningful minimal residual disease (MRD) negative responses observed across pre-specified subgroups.
• Preliminary data from the KOMET-007 Phase 1b expansion cohort showed robust clinical activity for ziftomenib in combination with 7+3 in newly diagnosed AML, achieving high CRc rates (93% in NPM1-mutant and 89% in KMT2A-rearranged AML).
• High rates of CR-MRD negativity were observed in the KOMET-007 trial (71% for NPM1-mutant AML and 88% for KMT2A-rearranged AML), suggesting deep and durable responses.
• The initiation of the KOMET-015 trial for ziftomenib in GIST expands the potential indications and market opportunity for the product candidate beyond leukemias.
• The company plans to initiate two global Phase 3 trials (KOMET-017-IC and KOMET-017-NIC) for ziftomenib in newly diagnosed AML in the second half of 2025, demonstrating a clear path for registrational studies.
• Collaboration revenue of $29.4 million for the six months ended June 30, 2025, and a $45.0 million milestone payment from Kyowa Kirin, significantly bolster financial resources.
• Cash, cash equivalents, and short-term investments of $630.7 million as of June 30, 2025, are projected to fund current operating expenses into 2027 and support the ziftomenib AML program through commercialization in the frontline combination setting with anticipated collaboration funding.

Negatives

• The company continues to incur significant operating losses, with a net loss of $(123.6) million for the six months ended June 30, 2025.
• High dependence on the successful development and commercialization of ziftomenib, which is still in clinical development and has not yet received commercial approval.
• Reliance on third-party contractors and organizations for conducting clinical trials and providing commercial supply introduces risks of unsatisfactory performance, delays, or failure to meet deadlines.
• The biopharmaceutical industry is highly competitive, with numerous major pharmaceutical and biotechnology companies developing treatments for cancer, potentially leading to market saturation or reduced commercial opportunity.
• Uncertainty surrounding insurance coverage and reimbursement status for newly approved products could limit market acceptance and the ability to generate significant revenue.
• The inherent risk of product liability exposure exists during clinical trials and will increase upon commercialization, potentially leading to substantial liabilities.
• The company's future success is highly dependent on retaining key executives and attracting/motivating qualified personnel in a competitive talent market.
• Vulnerability to unfavorable global economic conditions, including financial market volatility, interest rate changes, and inflation, could adversely affect business operations and capital access.
• Information technology systems and data, including those of third-party partners, are vulnerable to security incidents, cyberattacks, and system failures, which could disrupt operations and lead to adverse consequences.
• Operations are susceptible to interruptions from natural disasters, power loss, and other events beyond control, for which business interruption insurance may not provide adequate compensation.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business, particularly given reliance on international suppliers and manufacturers.

Risks

• High dependence on the success of ziftomenib, which is still in clinical development, and no assurance of regulatory approval or anticipated revenue.
• Discovery, preclinical, and clinical development activities focused on genetically defined cancers, a rapidly evolving area, may not lead to marketable products.
• Clinical drug development is lengthy, expensive, and uncertain; preclinical/early clinical results may not predict final results, leading to additional costs or delays.
• Product candidates may be used in combination with third-party drugs/biologics, some still in development, with limited control over their supply, regulatory status, or approval.
• Product candidates may cause serious adverse events or unacceptable side effects, delaying, limiting, or preventing development.
• Failure by the company or third-party collaborators to develop, validate, and obtain regulatory approval for a diagnostic testing platform could harm drug development strategy and operational results.
• Expectation to incur losses over the next several years and may never achieve or maintain profitability.
• As a clinical-stage company with no approved products and no historical product revenue, financial and operating results will vary significantly.
• Need to obtain substantial additional capital, which may cause dilution, restrict operations, or require relinquishing rights.
• Collaboration with Kyowa Kirin is important; cessation of efforts or termination of agreements could adversely affect business and future payments.
• Reliance on third-party contractors for clinical trials and commercial supply, with risks of unsatisfactory performance or missed deadlines.
• Inability or delays in obtaining required regulatory approvals in planned regions would impair commercialization and revenue generation.
• Approved products will be subject to extensive post-approval regulatory requirements, restrictions, or withdrawal, with penalties for non-compliance or unanticipated problems.
• Inability to obtain or maintain intellectual property protection, or insufficient scope, could allow competitors to commercialize similar products.
• Dependence on licensors to prosecute and maintain material patents and patent applications.
• Patent terms may be inadequate to protect competitive position for a commercially meaningful length of time.
• May not be successful in obtaining or maintaining necessary third-party intellectual property rights for the development pipeline.
• Inability to maintain confidentiality of trade secrets or other confidential information would harm business and competitive position.
• Intellectual property discovered through government-funded programs may be subject to federal regulations like march-in rights, limiting exclusive rights or ability to contract with non-U.S. manufacturers.
• Inability to protect intellectual property rights globally, including impacts from geo-political actions.
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, and payors.
• Building a limited marketing, sales, and distribution infrastructure; inability to fully develop capabilities or secure third-party agreements could hinder effective sales/marketing.
• Substantial competition from other companies developing or commercializing competing products.
• Uncertainty of insurance coverage and reimbursement status for newly-approved products.
• Product liability lawsuits could incur substantial liabilities and limit commercialization.
• High dependence on Chief Executive Officer and ability to attract/retain qualified personnel.
• Difficulties in managing growth due to expansion of development, regulatory, operations, medical affairs, market access, marketing, and sales capabilities.
• Unfavorable global economic conditions could adversely affect business.
• Compromised information technology systems or data could lead to adverse consequences.
• Business operations vulnerable to interruption by natural disasters, power loss, terrorist activity, and other events beyond control.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business.
• Stock price may fluctuate significantly, and difficulty selling shares based on current trading volumes.
• Price of common stock may be volatile and influenced by numerous factors beyond control.
• Broad discretion in the use of cash may not be effective.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell stock.
• Resale of shares covered by shelf registration statements could adversely affect market price.
• Increased costs and demands on management from complying with public company laws and regulations.
• Failure to maintain proper and effective internal controls could impair financial statements.
• Future sales and issuances of common stock or rights could result in dilution and cause stock price to fall.
• Anti-takeover provisions could delay or prevent a change of control.
• Charter documents provide exclusive forum for disputes, limiting stockholders' ability to choose a favorable judicial forum.
• Changes in tax laws or regulations applied adversely could have a material adverse effect.
• Ability to use net operating loss carryforwards and other tax attributes may be limited.
• No intention to pay cash dividends in the foreseeable future.
• Actions of activist stockholders could negatively affect business and stock value.
• Securities class action litigation could divert management attention and harm business.
• Employees, contractors, etc., may engage in misconduct or improper activities.
• Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations.

Future Outlook

Kura Oncology anticipates initiating two global, randomized, double-blind, placebo-controlled Phase 3 trials (KOMET-017-IC and KOMET-017-NIC) for ziftomenib in newly diagnosed NPM1-mutant or KMT2A-rearranged AML in the second half of 2025. Topline results from the MRD-negative CR accelerated endpoint in the KOMET-017-IC trial are expected in 2028. Preliminary data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib in combination with venetoclax and azacitidine in the frontline setting are expected in the second half of 2025. Preliminary data for KO-2806 as a monotherapy and in combination with cabozantinib are accepted for poster presentation at the ESMO Congress in October 2025, with expansion cohorts for the cabozantinib combination in advanced RCC expected to initiate in the second half of 2025. Data from the KURRENT-HN trial for tipifarnib and alpelisib are also accepted for poster presentation at the ESMO Congress in October 2025. The company expects research and development expenses to increase as clinical development activities for ziftomenib and FTI programs continue, and general and administrative expenses to rise to support increased R&D and pre-commercial activities. Cash, cash equivalents, and short-term investments are projected to fund operations into 2027, and with anticipated collaboration funding, support the ziftomenib AML program through commercialization in the frontline combination setting.

Management Comments

• We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
• Our pipeline consists of small molecule product candidates designed to target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes.
• We intend to pair our product candidates with molecular or cellular diagnostics to identify those patients most likely to respond to treatment.
• We plan to advance our product candidates through a combination of internal development and strategic partnerships while maintaining significant development and commercial rights.
• We expect our research and development expenses to increase in future periods as we continue clinical development activities for our ziftomenib and FTI programs.
• We expect our general and administrative expenses to increase in future periods to support our planned increase in research and development and pre-commercial activities.
• Based on our current plans, we believe that our cash, cash equivalents and short-term investments as of June 30, 2025 will be sufficient to enable us to fund our current operating expenses into 2027, and combined with anticipated collaboration funding under the Kyowa License Agreement, should support our ziftomenib AML program through commercialization in the frontline combination setting.

Industry Context

The biopharmaceutical industry, particularly in oncology, remains highly competitive and rapidly evolving, with a strong focus on targeted therapeutics and precision medicine. Kura Oncology's strategy aligns with this trend by developing product candidates for genetically defined cancers and utilizing companion diagnostics. The regulatory landscape is dynamic, with the FDA's Breakthrough Therapy Designation and Priority Review accelerating development pathways for promising candidates like ziftomenib. However, the industry faces increasing governmental scrutiny over drug pricing, exemplified by the Inflation Reduction Act (IRA) and recent executive orders, which could impact future revenues and reimbursement. The recent Loper Bright Enterprises v. Raimondo Supreme Court decision may also introduce additional legal challenges to regulatory guidance. The global economic environment, including inflation and financial market volatility, continues to pose challenges for capital access and operational costs. Cybersecurity threats are also a growing concern across the industry, requiring robust protective measures. Kura Oncology's collaboration with Kyowa Kirin reflects a common industry strategy to share development costs and leverage broader commercialization capabilities for global reach.

Comparison to Industry Standards

• Kura Oncology's ziftomenib is directly competing with other menin inhibitors in development, notably Syndax Pharmaceuticals, Inc.'s revumenib (Revuforj), which received FDA approval in November 2024 for relapsed or refractory KMT2A-rearranged acute leukemia and has a PDUFA target action date of October 25, 2025, for NPM1-mutant AML. This indicates a competitive race to market in the same therapeutic area and patient population.
• The 23% CR/CRh rate observed in KOMET-001 Phase 2 for relapsed/refractory NPM1-mutant AML, along with high MRD negativity rates, positions ziftomenib as a potentially significant treatment option, comparable to or potentially differentiated from other emerging therapies in this difficult-to-treat population.
• The planned initiation of two global Phase 3 trials (KOMET-017-IC and KOMET-017-NIC) for ziftomenib in newly diagnosed AML demonstrates a comprehensive and aggressive development strategy, aiming to establish ziftomenib as a frontline therapy, which is a common goal for leading oncology drug developers.
• The company's financial runway into 2027, supported by the Kyowa Kirin collaboration, is a strong position for a clinical-stage biopharmaceutical company, providing stability for ongoing and planned clinical programs compared to many peers who may face more immediate capital needs.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential for significant value creation from ziftomenib's regulatory progress (FDA Priority Review, PDUFA date) and strong clinical data. However, continued operating losses and the need for future capital raises could lead to dilution.
• **Employees:** Increased headcount and expansion of development, regulatory, operations, medical affairs, market access, marketing, and sales teams indicate growth opportunities, but also increased demands and potential for management challenges.
• **Customers (Patients & Healthcare Professionals):** Ziftomenib's progress offers a promising new treatment option for AML patients, particularly those with NPM1-mutations, and potentially for GIST. The combination trials aim to improve outcomes in newly diagnosed AML. Access and reimbursement will be critical for patient uptake.
• **Collaborators (Kyowa Kirin):** The Co-Promotion and Medical Affairs Agreement solidifies the partnership, outlining shared responsibilities and costs, which could lead to shared success or potential disputes if obligations are not met.
• **Suppliers & Contractors:** Continued reliance on third-party contractors for clinical trials, manufacturing, and supply chain activities, indicating ongoing business for these partners, but also risks if performance is unsatisfactory.

Next Steps

• FDA review of the ziftomenib NDA for relapsed or refractory NPM1-mutant AML, with a PDUFA target action date of November 30, 2025.
• Initiate the KOMET-017-IC (Intensive Chemotherapy) trial in the second half of 2025, evaluating ziftomenib with induction chemotherapy (7+3) in newly diagnosed NPM1-mutant or KMT2A-rearranged AML.
• Initiate the KOMET-017-NIC (Non-Intensive Chemotherapy) trial in the second half of 2025, evaluating ziftomenib with venetoclax plus azacitidine in newly diagnosed NPM1-mutant AML.
• Present preliminary data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib in combination with venetoclax and azacitidine in the frontline setting in the second half of 2025.
• Present preliminary data from the FIT-001 trial for KO-2806 as a monotherapy and in combination with cabozantinib at the European Society for Medical Oncology (ESMO) Congress in October 2025.
• Initiate one or more expansion cohorts for the combination of KO-2806 with cabozantinib in advanced Renal Cell Carcinoma (RCC) in the second half of 2025.
• Present data from the KURRENT-HN trial for tipifarnib and alpelisib at the ESMO Congress in October 2025.
• Continue enrollment in the KOMET-008 trial (ziftomenib in combination with gilteritinib, FLAG-IDA, or LDAC) and KOMET-015 trial (ziftomenib in GIST).
• Continue to build out marketing, sales, market access, distribution, and managerial capabilities in preparation for potential commercialization of ziftomenib.

Key Dates

Recommendation

Kura Oncology presents a compelling investment case with its lead product candidate, ziftomenib, demonstrating significant clinical and regulatory momentum. The FDA's acceptance of the NDA with Priority Review and a PDUFA date of November 30, 2025, de-risks the regulatory pathway considerably. The positive pivotal data from KOMET-001 in relapsed/refractory AML and robust data from KOMET-007 in newly diagnosed AML highlight ziftomenib's strong efficacy and potential across multiple patient populations. The strategic collaboration with Kyowa Kirin provides substantial funding and commercialization support, extending the financial runway into 2027 and supporting the AML program through commercialization. While the company continues to incur losses, this is typical for a clinical-stage biopharmaceutical firm on the cusp of potential commercialization. The expansion into GIST and the initiation of global Phase 3 trials further broaden the long-term value proposition. The near-term catalysts, strong clinical profile, and solid financial position make Kura Oncology a strong buy for investors seeking exposure to a high-potential oncology asset.

Keywords

Kura Oncology, ziftomenib, AML, NPM1-mutant, KMT2A-rearranged, menin inhibitor, oncology, biopharmaceutical, clinical trials, FDA approval, Breakthrough Therapy, Kyowa Kirin, KO-2806, FTI, GIST, HNSCC, precision medicine, drug development, Q2 2025 earnings